Market Cap 11.78B
Revenue (ttm) 2.94B
Net Income (ttm) 537.87M
EPS (ttm) N/A
PE Ratio 22.32
Forward PE 20.00
Profit Margin 18.30%
Debt to Equity Ratio 0.00
Volume 865,400
Avg Vol 1,288,100
Day's Range N/A - N/A
Shares Out 135.25M
Stochastic %K 26%
Beta 1.05
Analysts Strong Sell
Price Target $109.54

Company Profile

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; intervention...

Industry: Medical Devices
Sector: Healthcare
Phone: 610 930 1800
Address:
2560 General Armistead Avenue, Audubon, United States
ZacksResearch
ZacksResearch Mar. 10 at 2:57 PM
5 medical instrument stocks flashing serious short-term upside 👀 $ISRG $GMED $EW $ALC $IRMD are getting attention as AI tools, acquisitions, and new product pipelines fuel growth expectations — a combo that often sparks momentum in this space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-teaser-36722&ADID=SYND_STOCKTWITS_TWEET_2_2881459_TEASER_36722
0 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 1:57 PM
Five medical instrument stocks with significant short-term potential! 🚀 🤖 $ISRG leads the charge with AI-driven innovations, boasting a Zacks Rank #1 and a short-term price target indicating a 26% increase from its last close, with an upside of up to 52%. 💼 $GMED strengthens its position with strategic mergers, a debt-free balance sheet, and a promising pipeline, marked by a Zacks Rank #1 and a short-term target of a 24.7% gain, with an upside of up to 40.1%. 💔 $EW is advancing its Structural Heart business, supported by a Zacks Rank #2 and a short-term price target increase of 14%, with a maximum upside of 30.5%. 👓 $ALC capitalizes on its Vision Care innovations, with a Zacks Rank #2 and a short-term target increase of 13.9%, with an upside of up to 36.8%. 🩺 $IRMD expands with MRI-compatible products, holding a Zacks Rank #2 and a forecasted 19.9% rise, with an upside of 20%. Explore the full growth story here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-body-36721&ADID=SYND_STOCKTWITS_TWEET_2_2881459_BODY_36721
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 3:05 PM
$GMED quietly taking share — but don’t ignore the risks ⚖️ The company is gaining ground in musculoskeletal solutions with spine growth, rapid product launches, and strong cash. At the same time, macro headwinds and rising costs are real overhangs. Is this a durable growth story or a margin squeeze waiting to happen? Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2879182/is-this-the-right-time-to-add-globus-medical-stock-to-your-portfolio?cid=sm-stocktwits-2-2879182-teaser-36083&ADID=SYND_STOCKTWITS_TWEET_2_2879182_TEASER_36083
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 2:05 PM
Is $GMED a hidden gem in the medical device sector? 🤔 Despite macroeconomic headwinds, this Zacks Rank #3 stock has gained 14.7% over the past year, outperforming its declining industry. With a solid 18.8% average earnings surprise and strong financial stability, Globus Medical is showing potential. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2879182/is-this-the-right-time-to-add-globus-medical-stock-to-your-portfolio?cid=sm-stocktwits-2-2879182-body-36056&ADID=SYND_STOCKTWITS_TWEET_2_2879182_BODY_36056
0 · Reply
smartkarma
smartkarma Mar. 4 at 5:05 PM
$GMED | Globus Medical: Is the Post-Deal Integration Machine Turning NuVasive and Nevro Into a Real Musculoskeletal Powerhouse? "Globus Medical's third-quarter 2025 results reflect a balanced blend of growth and strategic maneuvers, marked by notable financial and..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/globus-medical-is-the-post-deal-integration-machine-turning-nuvasive-and-nevro-into-a-real-musculoskeletal-powerhouse
0 · Reply
erevnon
erevnon Feb. 26 at 5:48 PM
Wells Fargo maintains Globus Medical $GMED at Overweight and raises the price target from $98 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Feb. 26 at 4:16 PM
$GMED Wells Fargo raises target price to $104 from $98
0 · Reply
NorthStarStats
NorthStarStats Feb. 26 at 2:05 AM
I forgot to post yesterday's stocks. Hopefully they did well today: $PRME Score: 100, $GMED Score 100, $EDIT Score 100, $LRMR Score 100, $SGMO Score 100
0 · Reply
d_risk
d_risk Feb. 24 at 11:06 PM
$GMED - Globus Medical Inc - 10K - Updated Risk Factors GMED adds new risks around volatile US/global tariffs, AI-driven cyber/privacy and cost exposure, leadership transition to a new CEO, expanded NuVasive/Nevro integration and synergy shortfall risk, pandemic-driven elective surgery disruption, and Delaware/federal exclusive-forum bylaws that may deter shareholder litigation. #MedicalDevices #TariffVolatility #CybersecurityRisks #LeadershipTransition #ElectiveSurgeryImpact 🟢 Added 🟠 Removed https://d-risk.ai/GMED/10-K/2026-02-24
0 · Reply
EconomyEngine
EconomyEngine Feb. 24 at 9:36 PM
$QQQ $GMED Q4 EARNINGS HIGHLIGHTS 🔹 Revenue: $826.4M (Est. $792.72M) 🟢 🔹 EPS: $1.28 (Est. $1.11) 🟢 FY’26 Guide: 🔹 Revenue: $3.18B–$3.22B (Est. $3.163B) 🟡 🔹 EPS: $4.40–$4.50 (Est. $4.24) 🟢
0 · Reply
Latest News on GMED
Globus Medical, Inc. (GMED) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 10:07 PM EST - 13 days ago

Globus Medical, Inc. (GMED) Q4 2025 Earnings Call Transcript


Steven Cress' Top 10 AI Stocks (Recap & Update)

Feb 4, 2026, 6:50 PM EST - 4 weeks ago

Steven Cress' Top 10 AI Stocks (Recap & Update)

AIQ APP CIEN CLS CRDO GM HUT


Top 10 AI Stocks For 2026

Jan 20, 2026, 5:00 AM EST - 7 weeks ago

Top 10 AI Stocks For 2026

APP CIEN CLS CRDO GM HUT LITE


Globus Medical: Straightening Its Back

Nov 11, 2025, 10:00 AM EST - 4 months ago

Globus Medical: Straightening Its Back


Globus Medical, Inc. (GMED) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 9:56 PM EST - 4 months ago

Globus Medical, Inc. (GMED) Q3 2025 Earnings Call Transcript


Globus Medical Reports Third Quarter 2025 Results

Nov 6, 2025, 4:15 PM EST - 4 months ago

Globus Medical Reports Third Quarter 2025 Results


Is Wall Street Underestimating Globus Medical Stock's Potential?

Oct 22, 2025, 11:25 AM EDT - 4 months ago

Is Wall Street Underestimating Globus Medical Stock's Potential?


Globus Medical, Inc. (GMED) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:05 PM EDT - 7 months ago

Globus Medical, Inc. (GMED) Q2 2025 Earnings Call Transcript


Globus Medical Reports Second Quarter 2025 Results

Aug 7, 2025, 4:15 PM EDT - 7 months ago

Globus Medical Reports Second Quarter 2025 Results


Globus Medical: Obtaining My Backing Again

Jul 3, 2025, 12:10 PM EDT - 8 months ago

Globus Medical: Obtaining My Backing Again


Globus Medical Announces $500 Million Share Repurchase Program

May 15, 2025, 4:30 PM EDT - 10 months ago

Globus Medical Announces $500 Million Share Repurchase Program


Medical, Inc. Company Investigated by the Portnoy Law Firm

May 13, 2025, 6:28 PM EDT - 10 months ago

Medical, Inc. Company Investigated by the Portnoy Law Firm


Globus Medical, Inc. (GMED) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:32 PM EDT - 10 months ago

Globus Medical, Inc. (GMED) Q1 2025 Earnings Call Transcript


Globus Medical Reports First Quarter 2025 Results

May 8, 2025, 4:15 PM EDT - 10 months ago

Globus Medical Reports First Quarter 2025 Results


Globus Medical completes acquisition of Nevro Corp.

Apr 3, 2025, 8:31 AM EDT - 1 year ago

Globus Medical completes acquisition of Nevro Corp.


ZacksResearch
ZacksResearch Mar. 10 at 2:57 PM
5 medical instrument stocks flashing serious short-term upside 👀 $ISRG $GMED $EW $ALC $IRMD are getting attention as AI tools, acquisitions, and new product pipelines fuel growth expectations — a combo that often sparks momentum in this space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-teaser-36722&ADID=SYND_STOCKTWITS_TWEET_2_2881459_TEASER_36722
0 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 1:57 PM
Five medical instrument stocks with significant short-term potential! 🚀 🤖 $ISRG leads the charge with AI-driven innovations, boasting a Zacks Rank #1 and a short-term price target indicating a 26% increase from its last close, with an upside of up to 52%. 💼 $GMED strengthens its position with strategic mergers, a debt-free balance sheet, and a promising pipeline, marked by a Zacks Rank #1 and a short-term target of a 24.7% gain, with an upside of up to 40.1%. 💔 $EW is advancing its Structural Heart business, supported by a Zacks Rank #2 and a short-term price target increase of 14%, with a maximum upside of 30.5%. 👓 $ALC capitalizes on its Vision Care innovations, with a Zacks Rank #2 and a short-term target increase of 13.9%, with an upside of up to 36.8%. 🩺 $IRMD expands with MRI-compatible products, holding a Zacks Rank #2 and a forecasted 19.9% rise, with an upside of 20%. Explore the full growth story here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-body-36721&ADID=SYND_STOCKTWITS_TWEET_2_2881459_BODY_36721
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 3:05 PM
$GMED quietly taking share — but don’t ignore the risks ⚖️ The company is gaining ground in musculoskeletal solutions with spine growth, rapid product launches, and strong cash. At the same time, macro headwinds and rising costs are real overhangs. Is this a durable growth story or a margin squeeze waiting to happen? Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2879182/is-this-the-right-time-to-add-globus-medical-stock-to-your-portfolio?cid=sm-stocktwits-2-2879182-teaser-36083&ADID=SYND_STOCKTWITS_TWEET_2_2879182_TEASER_36083
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 2:05 PM
Is $GMED a hidden gem in the medical device sector? 🤔 Despite macroeconomic headwinds, this Zacks Rank #3 stock has gained 14.7% over the past year, outperforming its declining industry. With a solid 18.8% average earnings surprise and strong financial stability, Globus Medical is showing potential. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2879182/is-this-the-right-time-to-add-globus-medical-stock-to-your-portfolio?cid=sm-stocktwits-2-2879182-body-36056&ADID=SYND_STOCKTWITS_TWEET_2_2879182_BODY_36056
0 · Reply
smartkarma
smartkarma Mar. 4 at 5:05 PM
$GMED | Globus Medical: Is the Post-Deal Integration Machine Turning NuVasive and Nevro Into a Real Musculoskeletal Powerhouse? "Globus Medical's third-quarter 2025 results reflect a balanced blend of growth and strategic maneuvers, marked by notable financial and..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/globus-medical-is-the-post-deal-integration-machine-turning-nuvasive-and-nevro-into-a-real-musculoskeletal-powerhouse
0 · Reply
erevnon
erevnon Feb. 26 at 5:48 PM
Wells Fargo maintains Globus Medical $GMED at Overweight and raises the price target from $98 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Feb. 26 at 4:16 PM
$GMED Wells Fargo raises target price to $104 from $98
0 · Reply
NorthStarStats
NorthStarStats Feb. 26 at 2:05 AM
I forgot to post yesterday's stocks. Hopefully they did well today: $PRME Score: 100, $GMED Score 100, $EDIT Score 100, $LRMR Score 100, $SGMO Score 100
0 · Reply
d_risk
d_risk Feb. 24 at 11:06 PM
$GMED - Globus Medical Inc - 10K - Updated Risk Factors GMED adds new risks around volatile US/global tariffs, AI-driven cyber/privacy and cost exposure, leadership transition to a new CEO, expanded NuVasive/Nevro integration and synergy shortfall risk, pandemic-driven elective surgery disruption, and Delaware/federal exclusive-forum bylaws that may deter shareholder litigation. #MedicalDevices #TariffVolatility #CybersecurityRisks #LeadershipTransition #ElectiveSurgeryImpact 🟢 Added 🟠 Removed https://d-risk.ai/GMED/10-K/2026-02-24
0 · Reply
EconomyEngine
EconomyEngine Feb. 24 at 9:36 PM
$QQQ $GMED Q4 EARNINGS HIGHLIGHTS 🔹 Revenue: $826.4M (Est. $792.72M) 🟢 🔹 EPS: $1.28 (Est. $1.11) 🟢 FY’26 Guide: 🔹 Revenue: $3.18B–$3.22B (Est. $3.163B) 🟡 🔹 EPS: $4.40–$4.50 (Est. $4.24) 🟢
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 24 at 9:31 PM
$GMED Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.05 up 452.63% YoY • Reported revenue of $826.42M up 25.73% YoY • Globus Medical reaffirms full-year 2026 revenue guidance of $3.18B and updates non-GAAP diluted EPS guidance to $4.40 to $4.50, up from $4.30 to $4.40.
0 · Reply
Estimize
Estimize Feb. 24 at 4:00 PM
$GMED reports after the close, Estimize Consensus +0.06 EPS and +19.19M Revs compared to WS http://www.estimize.com/gmed/fq4-2025?utm_conte
0 · Reply
GitRichOrBuyTryin
GitRichOrBuyTryin Feb. 23 at 7:41 PM
$GMED IBD buy point triggered at $92.47 for GMED Bought GMED at $93.05 RSI &MACD looking good. They are also Reporting earning on 2-24-26 Prepare for liftoff!
0 · Reply
ANGRYmedINVESTOR
ANGRYmedINVESTOR Feb. 19 at 4:58 PM
$GMED STRONG BUY HERE AT A DISCOUNT IMO
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 5 at 6:54 PM
$GMED Share Price: $87.33 Contract Selected: Sep 18, 2026 $87.5 Calls Buy Zone: $9.78 – $12.08 Target Zone: $16.33 – $19.95 Potential Upside: 58% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Leondog1992
Leondog1992 Jan. 29 at 7:04 PM
$FROG $GH $GMED $IRTC $RKT Just remember money and this life is only Temporary. Jesus is king
1 · Reply
Leondog1992
Leondog1992 Jan. 29 at 4:43 PM
1 · Reply
ANGRYmedINVESTOR
ANGRYmedINVESTOR Jan. 27 at 6:56 PM
$GMED THE ONLY SPINE CO THAT MAKES MONEY
0 · Reply
rottieluvr3
rottieluvr3 Jan. 16 at 8:55 PM
$GMED Dumped this earlier when it was +.70%. Took my profits and ran. 💴💲💰
0 · Reply
Albino_Trader123
Albino_Trader123 Jan. 15 at 5:01 PM
$GMED Not an exciting name. But good for investors. They have the moat like $ISRG Rev and EPS healthy growth.
0 · Reply
IN0V8
IN0V8 Jan. 8 at 4:58 PM
$GMED Buy Barclays raises target price to $118 from $114 Jefferies raises target price to $115 from $105 RBC raises target price to $115 from $100
0 · Reply
Arcides
Arcides Jan. 8 at 4:55 PM
$GMED not what you wanna see after good news
0 · Reply